Musculoskeletal system diseases

The therapeutic area diseases of the musculoskeletal system is currently comprised of 19 medicinal products with 35 procedures regarding conditions such as arthritis, systemic lupus erythematosus (SLE) or rheumatoid arthritis. In its resolutions, the G-BA has divided the patients into 80 subpopulations. If these are weighted according to their patient share in the resolution, 0% of the subpopulations have seen a major additional benefit, 4.8% have seen a considerable additional benefit and a further 13.1% of the subpopulations have seen a minor additional benefit in relation to the comparative therapy. While 5.7% of the subpopulations have been able to record a non-quantifiable additional benefit in relation to the comparative therapy, 76.4% of the subpopulations have shown no additional benefit. This corresponds to 70% of all 2.08 million patients suitable for treatment with the assessed medicinal products.